EYLEA HD
EYLEA HD (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of several retinal vascular disorders. It is used in patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, the medication is approved for the treatment of macular edema following retinal vein occlusion.
How EYLEA HD Works
Aflibercept functions as a soluble decoy receptor that binds to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF). These proteins normally activate receptors on the surface of endothelial cells, leading to neovascularization and vascular permeability. By binding to these growth factors, aflibercept prevents them from interacting with their cognate receptors. This inhibition blocks the signaling pathways that contribute to abnormal blood vessel growth and fluid leakage in the eye.
Details
- Status
- Prescription
- First Approved
- 2023-08-18
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
EYLEA HD Approval History
What EYLEA HD Treats
4 indicationsEYLEA HD is approved for 4 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Macular Edema Following Retinal Vein Occlusion
EYLEA HD Target & Pathway
ProTarget
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pathway Context
VEGFR on blood vessels is activated by VEGF to promote angiogenesis
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
EYLEA HD Competitors
Pro2 other drugs also target VEGFR. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGFR). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to EYLEA HD
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EYLEA HD FDA Label Details
ProIndications & Usage
FDA Label (PDF)EYLEA HD is indicated for the treatment of: EYLEA HD is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Macular Edema Following Retinal Vein Occlusion (RVO) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Diabetic Retinopathy (DR) 1.4 Macular Edema Following Retinal Vein Occlusion (RVO)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.